Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)  by Norman, Jill
Biochimica et Biophysica Acta 1812 (2011) 1327–1336
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisReview
Fibrosis and progression of Autosomal Dominant Polycystic Kidney
Disease (ADPKD)☆
Jill Norman ⁎
UCL Centre for Nephrology, Division of Medicine, UCL Medical School Royal Free Campus, Rowland Hill Street London NW3 2PF, UK☆ This article is part of a Special Issue entitled: Polycy
⁎ Tel.: +44 207 794 0500x34988; fax: +44 207 317
E-mail address: j.norman@medsch.ucl.ac.uk.
0925-4439/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbadis.2011.06.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 February 2011
Received in revised form 18 June 2011
Accepted 21 June 2011
Available online 1 July 2011
Keywords:
Fibroblasts
Myoﬁbroblasts
Fibrosis
Extracellular matrix
Epithelial–ﬁbroblast interactions
Chronic kidney diseaseThe age on onset of decline in renal function and end-stage renal disease (ESRD) in autosomal polycystic
kidney disease (ADPKD) is highly variable and there are currently no prognostic tools to identify patients who
will progress rapidly to ESRD. In ADPKD, expansion of cysts and loss of renal function are associated with
progressive ﬁbrosis. Similar to the correlation between tubulointerstitial ﬁbrosis and progression of chronic
kidney disease (CKD), in ADPKD, ﬁbrosis has been identiﬁed as the most signiﬁcant manifestation associated
with an increased rate of progression to ESRD. Fibrosis in CKD has been studied extensively. In contrast, little is
known about themechanisms underlying progressive scarring in ADPKD although some commonality may be
anticipated. Current data suggest that ﬁbrosis associated with ADPKD shares at least some of the “classical”
features of ﬁbrosis in CKD (increased interstitial collagens, changes in matrix metalloproteinases (MMPs),
over-expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), over-expression of plasminogen
activator inhibitor-1 (PAI-1) and increased transforming growth factor beta (TGFβ) but that there are also
some unique and stage-speciﬁc features. Epithelial changes appear to precede and to drive interstitial changes
leading to the proposal that development of ﬁbrosis in ADPKD is biphasic with alterations in cystic epithelia
precipitating changes in interstitial ﬁbroblasts and that reciprocal interactions between these cell types drives
progressive accumulation of extracellular matrix (ECM). Since ﬁbrosis is a major component of ADPKD it
follows that preventing or slowing ﬁbrosis should retard disease progression with obvious therapeutic
beneﬁts. The development of effective anti-ﬁbrotic strategies in ADPKD is dependent on understanding
the precise mechanisms underlying initiation and progression of ﬁbrosis in ADPKD and the role of the
intrinsic genetic defect in these processes. This article is part of a Special Issue entitled: Polycystic Kidney
Disease.stic Kidney Disease.
8591.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Autosomal dominant polycystic kidney disease (ADPKD)
ADPKD is the most common lethal monogenic human disease
inherited as a dominant trait. It is estimated to affect at least
10 million individuals world-wide and to account for up to 10% of all
patients with end-stage renal disease (ESRD) requiring renal
replacement therapy (RRT) by haemodialysis or transplantation.
ADPKD is caused by a spectrum of mutations in a single gene, PKD1
in 85% of cases or PKD2 in the remaining 15% of cases, which encode
the proteins polycystin-1 (PC1) and polycystin-2 (PC2), respectively.
The age of onset of renal functional decline in ADPKD is highly variable
and can range from the 1st to the 8th decade [1]. Fifty percent of
ADPKD patients reach ESRD by approximately 50 years of age,
necessitating RRT, which, despite a few interesting leads to new
therapeutic strategies, is currently the mainline treatment for this
disease.ADPKD is characterized by the progressive enlargement of
multiple tubular cysts derived from all segments of the nephron. As
discussed in detail elsewhere in this special issue, a variety of
mechanisms have been identiﬁed which contribute to cyst formation
including inter alia, increased Epidermal growth factor (EGF)- and
cAMP-dependent epithelial cell proliferation, abnormal ﬂuid secre-
tion and apicobasal and planar polarity abnormalities [1–7]. Differences
in epithelial responses to growth factors is also evident, for example, the
negative regulation of EGF-dependent proliferation by Transforming
growth factor (TGF)β seen in normal human renal tubule epithelia,
is lost in ADPKD [2]. In addition, apoptosis is frequently seen in the
normal tubules of early-stage, pre-dialysis (E-) ADPKD kidneys
during the early phases of disease development, when there is
active proliferative expansion of multiple small cysts. ADPKD is a
progressive disease in which tubular epithelial cysts develop in
utero and continue to expand after birth, gradually displacing
normal renal parenchyma until N60% of normal nephrons are
destroyed, thereafter rapid renal functional decline ensues to end-
stage (ES-) ADPKD. The wide variability in age of onset of ESRD in
ADPKD patients is thought to be inﬂuenced by the particular PKD
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disease-associated modiﬁer genes and epigenetic factors [1,8–10]
although there is increasing evidence that haploinsufﬁciency alone
is sufﬁcient to elicit a cystic phenotype [11,12]. In patients with
PKD1 mutations, onset of renal failure occurs earlier than in those
with mutations in the PKD2 gene. The difference in severity is
thought to be due to the development of an increased number of
cysts in PKD1 rather than faster cyst growth [13].
Expanding renal cysts in ADPKD are surrounded by widely varying
degrees of interstitial ﬁbrosis. Although interstitial ﬁbrosis has been
described in models of PKD as well as in other genetic and acquired
cystic diseases and has been suggested to have a signiﬁcant impact on
the large variation in the age of onset and rate of subsequent renal
functional decline leading to ESRD in ADPKD [1], little is known about
the pathogenesis of this component of the disease. Further, it is
unclear whether ﬁbrosis in ADPKD shares common mechanisms with
ﬁbrosis in chronic kidney disease (CKD) of other etiologies and/or
whether there are disease-speciﬁc characteristics conferred by the
genetic mutation (PKD1 or PKD2).
2. Fibrosis in chronic kidney disease (CKD)
Progressive scarring or ﬁbrosis of the renal parenchyma leading to
organ failure is a characteristic feature of CKD of multiple etiologies
[14–17]. Regardless of the initiating insult, CKD presents a common
pathology of glomerulosclerosis and tubulointerstitial ﬁbrosis.
Importantly, the degree of tubulointerstitial involvement, rather
than glomerular injury, provides the best correlationwith progression
to ESRD and the need for RRT. Tubulointerstitial ﬁbrosis in CKD has
been studied extensively and a brief overview is provided here for the
purposes of comparison with ﬁbrosis in ADPKD. Fibrosis associated
with CKD presents a number of common characteristics including: a
persistent inﬂammatory cell inﬁltrate; an increase in interstitial cell
number with the appearance of myoﬁbroblasts expressing the
cytoskeletal protein α-smooth muscle actin (αSMA); tubular atrophy
and epithelial apoptosis; obliteration of the peritubular capillaries;
and, accumulation of extracellular matrix (ECM). The increase in
interstitial cell number is due to both increased proliferation and
decreased apoptosis of resident interstitial cells as well as migration of
cells into the tubulointerstitium.
Interstitial ﬁbroblasts/myoﬁbroblasts are the major players in
ﬁbrosis responsible for the deposition of ECM. Fibrotic myoﬁbroblasts
appear to have multiple origins, arising by differentiation of resident
interstitial ﬁbroblasts [18] and inﬁltrating cells including bone
marrow-derived progenitor cells (ﬁbrocytes) and inﬂammatory cells
[19]. A burgeoning literature also points to the transdifferentiation of
tubular epithelial cells (epithelial-to-mesenchymal transition) as an
additional source of myoﬁbroblasts as well as contributing to the loss
of tubular structures [20–22]. However, this remains an area of some
controversy [23] and may be context-dependent. Recent lineage
tracing studies and marker analyses have suggested that a proportion
of interstitial ﬁbroblasts derive from pericytes, the supporting cells
surrounding peritubular capillaries [24], and from capillary endothe-
lial cells by endothelial-to-mesenchymal transition [25,26]. Transition
of pericytes and endothelial cells to myoﬁbroblasts may also explain
the loss of peritubular capillaries which is invariably associated with
progressive ﬁbrosis and leads to tubulointerstitial hypoxia, a potent
driver of the ﬁbrotic process [27].
2.1. Extracellular matrix metabolism in ﬁbrosis
The hallmark of tubulointerstitial ﬁbrosis is the progressive
accumulation of ECM. In the normal kidney, the interstitial ECM
comprises only a small proportion of the tissue volume. The matrix is
composed of a variety of macromolecules including collagens,
ﬁbronectin, elastin, laminin, proteoglycans and non-collagenousglycoproteins. In tubulointerstitial ﬁbrosis, expansion of the ECM is
marked by accumulation of interstitial collagens and ﬁbronectin. In
addition to increased amounts of proteins, different isoforms may be
expressed in disease versus normal tissues; for example, the EDA
splice variant of ﬁbronectin appears early in the ﬁbrotic response. In
addition to changes in the composition of the ECM, modiﬁcation of
proteins, such as crosslinking of collagens by Transglutaminase 2, may
alter the mechanical properties of the matrix and render it resistant to
normal degradative processes [28]. Compositional and mechanical
changes in the ECM will lead to changes in cell–matrix interactions
which are mediated, in large part, by cell surface matrix receptors
such as integrins and sydecans [29]. Changes in matrix receptor
proﬁle in turn leads to alterations in downstream signalling, gene
expression and cell function. Thus changes in ECM may set in train a
self-perpetuating cycle whereby alterations in the ECM induce
changes is cell behaviour which in turn induce changes in ECM.
In ﬁbrosis, both increased production and decreased turnover of
ECM proteins contribute to matrix accumulation. Increased production
is regulated primarily at the level of transcription of matrix protein
genes while matrix turnover is mainly regulated by two proteolytic
cascades, one mediated by the matrix metalloproteinases (MMPs) and
their endogenous inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs), and the other by the serine proteases plasminogen activators
(uPA and tPA) and the plasminogen activator inhibitors (PAIs) [15].
Patterns of expression of MMPs in ﬁbrosis are complex with both
up- and down-regulation that may be time-, location- and cell type-
dependent. Interpretation of the in vivo effects is complicated: for
example, although an increase in MMP-2 might be assumed to be anti-
ﬁbrotic by increasing ECM turnover, over-expression of MMP-2
exacerbates ﬁbrosis, at least in part by promoting EMT [30]. Additional
complexity comes from the fact that, in addition to their matrix-
remodelling activities, MMPs cleave and activate a variety of biological
molecules including cytokines and chemokines. Thus, increased MMP
activity may increase expression of biologically-active, pro-ﬁbrotic
growth factors. The role of the TIMPs, of which 3 of the 4 family
members are expressed in the kidney, is similarly complex. Fibrosis in
vivo is invariably associated with an increase in TIMP-1 implying a
decrease in MMP activity and hence increased ECM accumulation,
however genetic deﬁciency of TIMP-1 does not reduce the ﬁbrotic
response [31]. Indeed, genetic deletion of TIMP-3 exacerbates myoﬁ-
broblast activation [32]. MMP-independent effects of TIMPs on cell
proliferation, survival and differentiation may also be relevant to the
pathogenesis of ﬁbrosis [33]. Increased expression of PAI-1 is also
characteristic of CKD [15,34]. Although it was assumed that the
pro-ﬁbrotic effects of PAI-1 were due to its role as an inhibitor of serine
proteases this has not proved to be the case, rather PAI-1 promotes
ﬁbrosis by increasingmacrophage andmyoﬁbroblast recruitment to the
tubulointerstitium [34]. tPA and uPA are increased in at least some
models of ﬁbrosis and tPA has been shown to be pro- rather than
anti-ﬁbrotic [34].
2.2. Mechanisms of ﬁbrosis
A number of mechanisms have been implicated in the initiation and
pathogenesis of ﬁbrosis in CKD [14,17,22,27,34,35] including i) an
imbalance in growth factors and cytokines with up-regulation of pro-
ﬁbrotic factors including inter alia, TGFβ1, Connective tissue growth
factor (CTGF), platelet-derived growth factor (PDGF), Fibroblast growth
factor (FGF)-2, Osteopontin and Endothelin (ET)-1 and concomitant
down-regulation of anti-ﬁbrotic factors such as Hepatocyte growth
factor (HGF) and Bonemorphogenic protein (BMP)-7; ii) dysregulation
of vasoactive factors with an increase in vasoconstrictors most notably
Angiotensin II (Ang II), and a decrease in vasodilators such as Nitric
oxide; iii) hypoxia as a consequence of microvascular injury and
obliteration; and iv) disruption of normal homeostatic interactions
between adjacent cell populations, in particular, the interactions
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close juxtaposition of epithelial cells, ﬁbroblasts, endothelial cells and
immune cells within the tubulointerstitium suggests important but as
yet largely unexplored, interactions between the microvascular endo-
thelium of peritubular capillaries and both tubular epithelial cells and
ﬁbroblasts as well as between immune cells (notably, monocytes and
macrophages) and tubulointerstitial cells [36,37].
2.3. Growth factors and signalling pathways activated in ﬁbrosis
Although numerous ﬁbrogenic factors have been reported, TGFβ1
is generally regarded as the pre-eminent ﬁbrogenic cytokine which is
up-regulated in every formof CKDboth in humans and in animalmodels
andactivation of the downstreamSmadsignallingpathway is a hallmark
ofﬁbrosis [38]. TGFβ also signals thoughavariety of non-Smadpathways
including ERK and JNK/p38 MAP kinase, small GTPAse and PI3K/Akt
pathways [39] many of which have been shown to be activated in
ﬁbrosis. Other intracellular pathways stimulated in ﬁbrosis include the
Ras pathway which drives ﬁbroblast proliferation [40], integrin-linked
kinase (ILK) [41] andWingless/Int (Wnt) [42].
2.4. Epigenetics and ﬁbrosis
Recent studies suggest a role for epigenetic changes in the
pathogenesis of ﬁbrosis. Epigenetic changes are heritable changes in
gene expression which do not involve changes in DNA sequence and
include DNA methylation and histone modiﬁcation. Recent exciting
ﬁndings suggest an important role for DNA methylation in the
perpetuation of the scarring process [43]. Further, prolonged exposure
of ﬁbroblasts to TGFβ leads to hypermethylation and epigenetic
changes which perpetuate the ﬁbrotic phenotype [43]. This study
highlights the importance of non-genetic DNA modiﬁcations in the
pathogenesis of disease.
2.5. microRNAs and ﬁbrosis
Another areaof rapidly expanding interest inﬁbrosis is that of the role
of microRNAs (miRNAs). miRNAs are short double-stranded RNA
sequences (20–23 nucleotides) which, in the main, regulate gene
expression at the translational level either by repressing mRNA
translation or reducing mRNA stability [44] although recent studies
suggest that miRNAsmay also enhancemRNA translation in response to
cellular stress [45].miRNAshavebeen implicated in the control of diverse
biological functions relevant to ﬁbrosis including proliferation, differen-
tiation and apoptosis and a number have been shown to be up- or down-
regulated in ﬁbrosis [46]. Several miRNAs are highly expressed in the
kidney compared to other organs including miR-192, -194, -204, -215
and -216 [47,48]. Expression of miR-192 is up-regulated in the mouse
model of unilateral ureteral obstruction (UUO), the rat remnant kidney
[49] and in diabetic mouse glomeruli and mesangial cells treated with
TGFβ [50]. In contrast, Krupa et al. [51] reported decreased expression of
miR-192 in human diabetic nephropathy. In TGFβ-treated mesangialFig. 1. Progressive ﬁbrosis in ADPKD. a–d. Toluidine blue-stained 1 μm plastic sections of:
b. E-ADPKD kidney with thickened basement membranes and increased numbers of inters
dilations; d. ES-ADPKD kidney with 3+ interstitial ﬁbrosis between epithelia of large cysts;
showing interstitial ﬁbroblasts and collagen ﬁbrils underlying a ﬂattened cyst-lining epithe
interstitial ﬁbroblasts in ES-ADPKD kidney (unpublished data); g. Avidin–biotin–peroxida
E-ADPKD kidney [2]. Note: Fibrosis scores: 1+ less than 20%; 2+ 20–40%; 3+ 40–60%; 4+cells, increased collagen α1(2) expression is mediated by miR-192
repression of the E-box repressor, Zeb2. Down-regulation of Zeb2
inducedmiR-216a and -217whichalso contributed to increased collagen
expression via suppression of PTEN and activation of Akt [52].miR-377 is
also up-regulated in the diabeticmouse kidney and increases expression
of ﬁbronectin via down-regulation of p21-activated kinase and super-
oxide dismutase [53]. Although this is still a verynewﬁeld, it seems likely
that miRs will become targets for novel anti-ﬁbrotic therapies.
3. ADPKD and progression
Although, in a small subset of PKD patients, very early onset ESRD
has been associated with the location (N-terminal) of PKD1 mutation
[54], in the vast majority of cases, no predictive link between
progression and mutation has been found. Onset of ESRD in patients
with a PKD2 mutation is delayed compared to PKD1 mutations [13].
Similar to the correlation between tubulointerstitial ﬁbrosis and
progression of CKD, in ADPKD patients the degree of ﬁbrosis has been
identiﬁed as the most signiﬁcant and variable manifestation that is
clearly associated with an increased rate of progression to ESRD
[54–56]. However, relatively little is known about the mechanisms
underlying ﬁbrosis in ADPKD. Unlike in CKD where kidney size is
unchanged or reduced, ADPKD kidneys enlarge dramatically and
progressively throughout the disease course even into end-stage
disease apparently as a result of both cystic epithelial and interstitial
expansion [1,57,58]. Although some commonality in the mechanisms
underlying ﬁbrosis in ADPKD and CKD may be anticipated, it seems
likely that the underlying genetic defect will also contribute unique
disease- and stage-speciﬁc processes whichmay provide novel targets
for therapeutic intervention.
3.1. Inﬂammation and ﬁbrosis
One of the hallmarks of ﬁbrosis is a persistent inﬂammatory
inﬁltrate [36,37]. Inﬂammatory cells have also been observed in
ADPKD kidneys often in association with expanding cysts. Gene
expression proﬁling of end-stage ADPKD kidneys revealed expression
of genes associated with immune or inﬂammatory responses [59].
Increased expression of PAI-1 in cystic epithelial may also suggest an
increased inﬂammatory response [34].
3.2. Extracellular matrix (ECM)
Pathological examination of human ADPKD kidneys compared to
age-matched controls [2,57,60–63] as well as phenotypic and
genotypic animal models of PKD [64,65], show abnormalities in
peri-cystic ECM deposition in basement membranes and the inter-
stitium as well as increased numbers of interstitial cells. Early-stage,
pre-dialysis ADPKD kidneys are characterized by proliferative expan-
sionof cyst-liningepithelial cells and alterations in theECMcomposition
and thicknessof thebasementmembranes (Fig. 1b versus a). Correlative
in vivo/in vitro analyses of human ADPKD (PKD1mutant) cyst epitheliaa. Normal human kidney with thin basement membranes and little interstitial space;
titial cells; c. ES-ADPKD kidney with 2+ interstitial ﬁbrosis between cystic epithelial
e. Transmission electron micrograph of ES-ADPKD kidney with 4+ interstitial ﬁbrosis
lia cell [57]; f. Immunoﬂuorescence of collagen type I underlying cyst epithelia and in
se–aminoethylcarbazole immunohistochemistry of focal accumulation of tenascin in
N80% on analysis of 10 random pathology sections.
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abnormalities of ECM composition and turnover including alterations
in collagen types I, III and IV, ﬁbronectin and in heparan sulphate
proteoglycan (HSPG) turnover, with the resultant increase in cystic
epithelial proliferation [7,60]. In end-stage (ES-)ADPKD kidneys, a
variable degree of expansion of the interstitial compartment is seen due
to progressive accumulation of ﬁbrogenic cells (ﬁbroblasts) and
collagen ﬁbrils (Fig. 1c–e). Gene expression analyses identiﬁed global
increases in interstitial collagens type I and type III as well as in the
basement membrane collagen type IV. Immunoﬂuorescence analysis
localized these increases to the basement membrane structures
surrounding small cysts as well as in the ﬁbroblasts deep in the
interstitium of ES-ADPKD kidneys (Fig. 1f). The development of renal
ﬁbrosis in ADPKD is characterized by focal changes. For instance,
tenascin, which is seen as a thin linear, homogeneous lining between
tubules in normal human kidneys is concentrated in focal areas of
matrix accumulation in closeassociationwith thebasementmembranes
of epithelia lining small cysts that are particularly prevalent in E-ADPKD
kidneys (Fig. 1g). Consistent with ﬁndings in CKD increased EDA-FN
expression was recently reported in Pkd1-null mice [66]. Fascinating
recent ﬁndings in zebraﬁsh suggest the polycystins may directly
regulate collagen production and suggest that over-production of
collagen may be a consequence of polycystin loss of function [67].
3.3. ECM turnover
The integrity and amount of ECM is maintained, at least in part, by
regulation of matrix turnover. A number of studies have reported
alterations in MMPs and TIMPs in animal models of PKD [68] and
present a complicated and often apparently conﬂicting picture. In a rat
model of PKD, epithelial expression of MMP-2 decreased [69] while
MMP-14 (MT1-MMP) increased [70]. MMP-14 expression was also
increased in ﬁbroblasts in the vicinity of both cystic and non-cystic
tubules in this model. In contrast to the ﬁndings in the rat, tubules
from the Cpk mouse (a model of ARPKD in which cilial cystein is
absent) in vitro secreted increased MMP-2 and also MMP-9 [71].
Recently Hassane S et al. reported increased MMP-2 and MMP-14
gene expression in the kidneys of Pkd1-mutant mouse models [66].
Data on matrix-remodelling enzymes and their inhibitors in human
ADPKD is sparse. Compared to controls, serum levels of MMP-1,MMP-
9 and TIMP-1 were reported to be increased in ADPKD patients [72].
A comparative analysis of MMP-2, MMP-9, stromelysin (MMP-3),
TIMP-1 and-2 and PAI-1 in tissue sections from age-matched normal,
E- and ES-ADPKD kidneys demonstrated a consistent pattern of
increased MMP expression in the epithelia of small cysts in E-ADPKD
human kidneys (Fig. 2b versus a) and in the interstitial ﬁbroblasts in
ES-ADPKD kidneys (Fig. 2c). TIMP-1 was also increased and localized
to interstitial ﬁbroblasts in ES-ADPKD kidneys (Fig. 2d) while increased
PAI-1, was characteristic of ES-ADPKD cystic epithelia (Fig. 2e) (our
unpublished data). PAI-1 expression was also reported to increase in
Pkd1-deletion mouse models [66]. The recent demonstration of
fragments of collagens I and III in urine of young, dialysis-independentFig. 2. Immunohistochemistry of MMP-2, TIMP-1 and PAI-1 in human ADPKD. a. MMP-2 expr
showing strong staining ofMMP-2 in epithelia lining small cysts; c. ES-ADPKD showingMMP
e. PAI-1 in epithelia lining large cysts in ES-ADPKD (unpublished data).APDKD patients highlights the importance of ECM remodelling in
disease and may suggest disease-speciﬁc changes in proteases [73].
Interestingly, there was both up-regulation and down-regulation of
particular fragments suggesting a complex interplay of accumulation
of some matrix components and turnover of others. A detailed time-
course of protease activity, expression of protease inhibitors andmatrix
proteins in slowly progressive models which closely mimic the human
diseasemay provide insight into the role of ECMmetabolism in disease.
3.4. ECM receptors
Cells and ECM interact in a reciprocal fashion to regulate
proliferation, differentiation and function. These cell–matrix interac-
tions are mediated via specialized matrix receptors; the integrins and
proteoglycan-containing syndecans, which act in concert with growth
factors and their receptors [74]. At points of cell–matrix interaction,
integrins and proteoglycans are clustered into focal adhesion
complexes [75] that provide a dynamic nucleation site for the
activation of multiple intracellular signaling pathways to regulate
gene expression and cell function [75,76]. The components of focal
adhesions are diverse and include scaffold proteins, actin-binding
proteins, GTPases, kinases such as focal adhesion kinase (FAK), src and
fyn, phosphatases and lipases. The interdependence of matrix,
receptors, signalling and gene expression means that changes in one
component will inevitably lead to altered cell function. Changes in
matrix receptor expression in a variety of cell types have been
described in CKD and are implicated in the pathogenesis of
progressive renal ﬁbrosis [29]. In ADPKD, the changes identiﬁed to
date are conﬁned to the cystic epithelial cell and show increased
expression of α2β1integrin and syndecan-4 [62,63] (our unpublished
data), integrin α8 [77], αv [78] and β4 [79]. Furthermore, recent
studies have also identiﬁed high levels of expression and alterations in
the polarized distribution of integrin-associated phospho-FAK in
E-ADPKD cystic epithelia suggesting activation of matrix receptor-
mediated intracellular signalling. To date no detailed analysis of
ﬁbroblast matrix receptor expression in ADPKD has been performed
but pathogenically-relevant changes might be anticipated.
3.5. Growth factors and signalling pathways
A number of growth factors implicated in ﬁbrosis are up-regulated
in ADPKD. EGF and EGF family ligands have been shown to be
important mediators of cystic epithelial proliferation [2,5]. TGFβ, the
major ﬁbrogenic cytokine, is highly expressed in cystic epithelia in
human ADPKD kidneys [2,59], Han: SPRD-Cy/+ rats [80] and Pkd-1
deletion mouse models [66]. Studies in rodent models suggest that
increased TGFβ expression and signalling correlates with later stages
of the disease implicating it in progression (and ﬁbrosis) rather than
cyst initiation [66]. Levels of FGF-1 are also increased in end-stage
human ADPKD [81].
As discussed elsewhere in this special issue, a number of intracellular
signalling pathways are activated in cystic lining epithelial cells inession in normal human adult kidney showing little reaction product (red); b. E-ADPKD
-2 staining in interstitial cells; d. TIMP expression in interstitial ﬁbroblasts in ES-ADPKD;
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immunohistochemical analysis showed increased phospho-JNK expres-
sion in interstitial cells of ES-ADPKD kidneys (our unpublished data),
however the speciﬁc pathways involved in ﬁbrosis associated with
ADPKD remain to be deﬁned.3.6. Myoﬁbroblast differentiation
An increase in interstitial cell number and the appearance of
myoﬁbroblasts expressing cytoskeletal αSMA, are cardinal features of
ﬁbrosis and these cells are thought to play a major role in ECM
accumulation [19]. Immunohistochemical staining of αSMA in human
ADPKD kidneys showed the focal appearance of αSMA staining in
some interstitial cells in early disease with more extensive and
marked expression in ES-APDKD, consistent with accumulation of
myoﬁbroblasts and interstitial ECM expansion in the later stages of
the disease (Fig. 3). Increased numbers αSMA-positive cells were also
observed in Pkd1-deletion mouse models where they appeared as a
layer around cysts [66]. Studies on expression proﬁling of end-stage
APDKD kidneys and kidneys of Han: SPRD-Cy/+ rats also reported
increased expression of smooth muscle proteins indicative of
myoﬁbroblast expansion [59,80]. Calcium is reported to play an
important role in myoﬁbroblast differentiation [82], given that PC2
acts as an endoplasmic reticulum calcium channel, it is interesting to
speculate thatmutations in this protein and alterations in intracellular
Ca levels may have pathologically-relevant effects on ﬁbroblast
differentiation. As mentioned in the context of CKD, the origin of
myoﬁbroblasts in ﬁbrosis remains controversial with a variety of cell
sources potentially contributing to the increased number of αSMA-
positive cells. In ADPKD, the derivation of these cells is unknown
though it seems likely that increased proliferation and differentiation
of interstitial ﬁbroblasts will account for at least some of the increase
[81]. Expression proﬁling studies of end-stage ADPKD kidneys and
kidneys of the phenotypic ADPKD model, the Han: SPRD-Cy/+ rat,
showing increased expression of gene sets associated with EMT
suggest this may be a pathogenic factor in ADPKD [59,80]. Marker
studies in the genotypic ARPKD Pck rat model also suggest that cystic
epithelial cells may express mesenchymal markers [83]. TGFβ
expression is elevated in ADPKD and TGFβ readily induces EMT in
normal tubular epithelial cells in vitro. However, based on immuno-
histochemical staining for Fsp1 (a ﬁbroblast marker) and αSMA, a
recent study in mice with Pkd1-deletion concluded that if EMT
contributes to ﬁbrosis, the contribution is likely to be small [66]. Two
other lines of evidence mitigate against a major contribution from
EMT. Many of the demonstrations of EMT rely on changes in
expression of epithelial and mesenchymal markers rather than
functional changes. For bona ﬁde EMT cells must leave the tubular
structure and migrate into the tubulointerstitium a process that
requires the dissolution of the basement membrane however in
ADPKD the basement membrane is frequently thickened rather than
rareﬁed [57] and in vitro studies suggest cystic cells adhere moreFig. 3.Myoﬁbroblast accumulation in ADPKD. Immunohistochemistry of αSMA (red deposit
reaction product in the interstitium; c. ES-ADPKD showing strong reaction product in the ﬁstrongly to the ECM and are less migratory than their normal
counterparts [84].
Expression studies comparing normal human proximal tubular
cells, early and end-stage ADPKD epithelial cells in vitro showed
increased expression of MMP-2, αSMA and heat shock protein (HSP)
47, a chaperone protein involved in collagen metabolism and
up-regulated in ﬁbrosis, in E- and ES-ADPKD. Levels of E-cadherin
were decreased in ES- but not E-ADPKD epithelia (our unpublished
data). While these data may suggest EMT can occur in cystic epithelial
cells these changes may also represent de-differentiation of the
epithelia. Whether ﬁbrocyte-, endothelial-, pericyte- or inﬂammatory
cell-to-mesenchymal transdifferentiation occurs in ADPKD to increase
the number of interstitial cells has not been examined. Lineage tracing
studies will be required to deﬁne the origin(s) of the interstitial cells
in ADPKD.
3.7. Expression of PC1 and PC2
The PKD gene products Polycystin-1 (PC1) and Polycystin-2 (PC2)
are localised to a number of cellular sites including on the plasma
membrane at sites of cell–cell and cell–matrix interactions, in the
endoplasmic reticulum, the nucleus and most importantly, the
primary cilium where the polycystin complex is thought to act as a
ﬂow sensor for epithelial cells [85].
The PKD1 gene encoded PC1 is a large (~460 kDa) trans-
membrane protein with a large extracellular region containing a
variety of domains associated with protein-protein and protein–
carbohydrate interactions, 11 trans-membrane domains and a short
cytoplasmic tail. Overall the structure of PC1 suggests a receptor or
adhesion molecule and interactions with a large number of proteins
including PC2, have been reported (reviewed in Ref. [86] and
elsewhere in this special issue). PC1 is highly expressed in the
developing kidney, predominantly in the ureteric bud-derived
collecting tubules. In normal kidneys it is down-regulated after birth
and restricted to inner medullary collecting ducts where it has been
localized to the apical-lateral membranes and is thought to play a role
in the maintenance of normal differentiation, including lumen size
[1,58,87]. Since all ADPKD patients are heterozygous for a germ-line
PKD1or PKD2mutation and second somatic “hits”mayalso occur, it is not
surprising that analysis of numerous (N200) ADPKD (PKD1) kidneys has
shown a wide variation in expression of PC1 protein in cystic epithelia
[84]. In ADPKD, low, moderate or high levels of PC1 expression are seen
in cystic epithelia [84], although this is often associated with
abnormal cellular distribution including nuclear localisation of the
C-terminal tail [88,89] and, presumably, abnormal protein function. In
general, higher levels of PC1 are seen in E-ADPKD epithelia lining small
cysts than in ES-ADPKD cyst-lining epithelia. Interestingly, although
interstitial PC1 in normal kidneys has occasionally been demonstrated in
vascular smooth muscle cells surrounding small vessels this has only
been achieved after extreme antigen unmasking procedures [90], while
in ES-ADPKD kidneys, PC1 was detected in ﬁbroblasts within the ﬁbrotic
interstitium (our unpublished data). PC2 is a much smaller (~110 kDa)s). a. Normal human adult kidney showing no reaction; b. E-ADPKD showing focal, light
brotic interstitium (unpublished data).
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tails both of which are intracellular. PC2 functions a non-selective cation
channel that transports calcium from the endoplasmic reticulum whose
function is thought to be to regulate intracellular calcium [85,91 and
reviewed elsewhere in this special issue]. The pathological relevance of
expression of interstitial expression of polycystins remains to be
established but the recent link between loss of polycystin function and
increased collagen production [67] raises fascinating questions about the
potential role of these proteins in ﬁbrosis.
3.8. Vascular remodelling, hypoxia and ﬁbrosis
Loss of peritubular capillaries and tissue hypoxia is a characteristic
of tubulointerstitial ﬁbrosis in CKD and is regarded as a ﬁnal common
pathway to ESRD. However, in this setting, peritubular capillary injury
is a consequence of glomerular injury since the peritubular network is
fed by the glomerular outﬂow. This scenario is not reiterated in
ADPKD where cystic development and expansion are independent of
glomerular alterations. However ADPKD cyst formation in human and
in animal models is accompanied by vascular abnormalities [1,92,93]
and morphological analyses provide evidence of disruption of the
normal peritubular microvasculature. ADPKD cyst walls contain an
extensive but abnormal capillary network and suggest that endothe-
lial cells express MMP2, integrin αvβ3 and Vascular endothelial
growth factor receptor (VEGFR)-2 but not VEGFR-1 [94]. In addition to
the renal defects, ADPKD is associated with serious extra-renal
vascular complications including hypertension, intra-cerebral aneu-
rysms, aortic dissections, sclerotic vascular changes and vessel
fragility. Hypertension is the most common presenting clinical
manifestation of ADPKD and can be detected up to two decades
prior to ESRD, it is thought to be due to abnormalities in the renin-
angiotensin system (RAS; [95,96]). A body of evidence suggests that
endothelial dysfunction in ADPKD, which precedes hypertension in
these patients, is associatedwith altered vasoconstriction as a result of
changes in the RAS, up-regulation of ET-1 and decreased nitric oxide
(NO) release apparently due to diminished constitutive nitric oxide
synthase (cNOS) activity [97–100]. A similar imbalance of vasoactive
factors is a contributory factor in ﬁbrosis in CKD. Other elements of the
vasculature are also affected in ADPKD, including abnormalities in
calcium regulation which have been implicated in functional changes
of ADPKD vascular smooth muscle cells [101,102].
Studies in humans and in rodent models provide evidence of
hypoxia in APDKD kidneys.
Hypoxia-inducible transcription factors (HIFs) were differentially
expressed in cystic epithelial cells (HIF-1α) and pericystic stromal
cells, inﬂammatory cells and endothelium (HIF-2α) [103]. Gene
proﬁling of PKD1 cysts displayed a rich proﬁle of gene sets associated
with hypoxia [59]. While hypoxia in ADPKD is posited as a driver of
pericystic hypervascularity providing expanding cysts with nutrients
it may also drive a pro-ﬁbrotic response particularly in the interstitial
cells [27].
3.9. Epigenetic changes, miRNA and ﬁbrosis
As alluded to earlier, two rapidly evolving areas of ﬁbrosis research
are the role of epigenetic changes and the role of miRNAs in
progressive scarring. The role of both these processes in ADPKD
ﬁbrosis is at this stage, largely speculative but worthy of investigation.
Are epigenetic changes in ADPKD ﬁbrosis the same as those identiﬁed
in CKDwhere TGFβ induces methylation of target genes to perpetuate
the ﬁbrotic phenotype [43]? Increased expression of TGFβ in ADPKD
may suggest this is likely to be the case particularly as ADPKD
ﬁbroblasts retain the ﬁbrotic phenotype in culture in the same way as
other ﬁbrotic ﬁbroblasts. Alternatively or in addition, there may be
disease-speciﬁc epigenetic changes.While conclusive evidence of miR involvement in APDKD is
currently lacking it seems likely that identiﬁcation of pathologically-
relevant up- and down-regulation of different miRNAs will be
forthcoming. A recent publication [104] implicated miR15a in hepatic
cystogenesis in a rat model of PKD; decreased miR15a was associated
with up-regulation of its target cell division cycle (Cdc) 25A, increased
proliferation and cyst growth. The question here too is whether
miRNA-induced changes in ADPKD ﬁbrosis will be the same as in
other forms of CKD or are there disease-speciﬁc alterations?
4. ADPKD ﬁbroblasts in vitro
4.1. ADPKD vs normal ﬁbroblasts
Numerous in vitro studies have compared normal human renal
tubular epithelial cells with ADPKD cyst epithelia and have identiﬁed
a variety of functional differences in cystic epithelial cells compared to
their normal counterparts including increased proliferation, altered
sensitivity to growth factors, increased adhesion of ECM, decreased
migration, abnormal apical–basal polarity and altered secretion
[2,5,60,85].
Studies comparing ﬁbroblasts from normal and ﬁbrotic tissues
have shown that cells retain the ﬁbrotic phenotype in vitro. Although
studies on ADPKD ﬁbroblasts are limited, comparison of primary
cultures of age-matched normal human kidney and ADPKD (PKD1
mutations) ﬁbroblasts from E- and ES-ADPKD kidneys show disease-
and stage-speciﬁc differences [81]. Compared to age-matched normal
cells, both E- and ES-ADPKD ﬁbroblasts in vitro show an enhanced
proliferative response to selected growth factors including FGF-1,
PDGF, TGFβ, Insulin-like growth factor (IGF)I and IGFII but not EGF.
ES-ADPKD ﬁbroblasts are capable of growth in soft agar [81]. ADPKD
ﬁbroblasts synthesized and secreted more FGF-1 [81] and FGF-1
elicited a more rapid and persistent tyrosine phosphorylation of
intracellular proteins in this cell type compared to normal renal
ﬁbroblasts. ADPKD ﬁbroblasts secreted high levels of uPA which was
further enhanced by FGF-1 [81]. In addition to increased FGF-1
expression, ES-ADPKD ﬁbroblasts express increased levels of mRNAs
for TGFβ, HSP47, MMP-2 consistent with a pro-ﬁbrotic phenotype.
Expression of αSMA was also up-regulated (unpublished data). Both
normal and ADPKD ﬁbroblasts expressed PKD1 mRNA and PC1
protein, however PKD1mRNA was increased in ES-ADPKD ﬁbroblasts
compared to age-matched, normal counterparts (unpublished data).
4.2. Fibroblasts and cilia
Polycystins are identiﬁed as focal adhesion, cell–cell adherens
junction and ciliary proteins and ciliary defects in cyst epithelial cells
have been implicated in the pathogenesis of ADPKD [1,85,86,91]. Less
well recognized is the observation that ﬁbroblasts, including human
kidney ﬁbroblasts, also possess a primary cilium (Fig. 4). Cilia are
thought to act as ﬂow-, chemo- and mechano-sensors and together
with focal adhesions and cell–cell adherens junctions, play an
important role in integrating signaling pathways [105–107]. It has
recently been shown that in ORPK (IFT88(Tg737Rpw)) mouse
ﬁbroblasts in which ciliary assembly is defective, responses to
PDGFAA are abnormal and wound healing is defective [108]. Also of
interest is the observation that, cilia are reduced in cells treated with
TGFβ. The effect of PKD1 or PKD2 mutations on cilia and adult
ﬁbroblast function in the context of ﬁbrosis is a question of
considerable interest particularly as signalling systems that may be
co-ordinated by the cilium include PDGFRα, Hedgehog and Wnt
pathways which are also implicated in ﬁbrosis. Some insight into the
effects of genetic deletion of ﬁbroblasts may be gained from studies in
mouse embryonic ﬁbroblasts (MEFs). Pkd1−/− MEFs have been
reported to show increased proliferation and increased cell size
[109]. Other investigators have reported reduced migration in Pkd1-
a b c
Fig. 4. Quiescent normal human kidney ﬁbroblasts in vitro express primary cilia. a. Scanning electron micrograph showing primary cilium (arrowhead); b. Immunoﬂuorescence of
nuclei stained with DAPI (blue) and cilia (arrowhead) stained with FITC-labelled antibody to acetylated tubulin (green), a marker of cilia; low power ﬁeld showing multiple nuclei
each with an associated cilium; c. High power detail (unpublished data).
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demonstration of cilia in other mesenchymal cells including vascular
smooth muscle cells [111,112] and changes in cilia have been
implicated in vascular abnormalities in ADPKD.
5. Epithelial–ﬁbroblast interactions, ADPKD and ﬁbrosis
One of the recurrent themes that emerges in looking at ﬁbrosis in
ADPKD is that cystic changes in the epithelium are associatedwith local
changes in adjacent ﬁbroblasts. This is particularly striking in detailed
chronological studies in animal models, for example, in the Han:SPRD
rat model of ADPKD [113] increased interstitial cell proliferation and
matrix deposition is associated with sites of increased epithelial cell
proliferation and thickened basement membrane. Similarly, in Pkd2
mutant mice as well as in human ADPKD there was a strong correlation
between cyst proliferation and ﬁbrosis score [114]. Likewise early
alterations in synthesis and secretion of MMPs and TIMPs in ADPKD
kidneys appear to precede interstitial changes [115]. Collectively these
data suggest anepithelial cell-initiatedmechanism forﬁbrosis in ADPKD
and imply an important role for epithelial–ﬁbroblast interactions in the
pathogenesis of this disease.
Classical embryological experiments ﬁrst demonstrated the es-
sential nature of reciprocal, sequential interactions between epithelial
and mesenchymal cells for the normal growth and differentiation
of the developing kidney [116,117]. In the adult organ, epithelial–
stromal interactions, mediated by direct cell contact, the ECM and
diffusible paracrine factors [118–120], continue to play an important
role in maintaining normal tissue homeostasis and in tissue repair
following injury. Dysregulation of epithelial–stromal interactions has
been implicated in the pathogenesis of a variety of diseases including
various cancers. In ﬁbrosis it is proposed that dysregulated function of,
and impaired communication between, epithelial and ﬁbroblastic
cells prevents the resolution of the wound-repair response following
injury, leading to an on-going scarring process. Furthermore, in CKD,
disruption of interactions between tubular epithelial cells and the
underlying ﬁbroblasts may be an early event in the pathogenesis of
ﬁbrosis with tubular cell injury induced by, for example, by proteins
and cytokines in the ﬁltrate from damaged glomeruli, leading to
activation of the underlying ﬁbroblasts which in turn exacerbate
tubular damage. However, since ADPKD cysts close off from the
nephron of origin rapidly after their initiation [1], this mechanism is
unlikely to be signiﬁcant in ADPKD. While altered tubular epithelial–
interstitial ﬁbroblast interaction is an attractive mechanism to explain
how glomerular injury is transmitted to the tubulointerstitial compart-
ment relatively few studies have examined themechanismsof interaction
between these two cell types [119–121]. Interestingly, our previous
studies identiﬁed a paracine, PDGF-mediated, regulatory loop between
inner medullary collecting duct epithelial cells and medullary ﬁbroblasts
[119] that was not apparent between proximal tubular epithelial cells
and cortical ﬁbroblasts, highlighting not only the importance of tubular
epithelial–interstitial ﬁbroblast interactions but raising the possibilityof segment-speciﬁc regulatory interactions. Reciprocal effects of ﬁbro-
blasts on epithelial cells to drive a ﬁbrotic response have been demon-
strated in othermodels, for exampleWnt-4-producingﬁbroblasts (αSMA
and Col1a1 positive) placed under the renal capsule induce tubular
destruction [42].
The primary defect in ADPKD is caused by alterations in the
development and differentiation of renal tubule epithelial cells
leading to inappropriate, persistent proliferation of these cells after
birth and consequent cystic expansion. Many factors can inﬂuence
proliferation of epithelial cells including the secretion of growth
factors and accessibility to their functional receptors as well as the
composition of the basement membrane and ECM from which
epithelial cells receive instructive signals. A number of studies have
shown that cyst-lining ADPKD epithelia are hyper-proliferative in vivo
and parallel in vitro studies have shown this to be due to hyper-
responsiveness to EGF and cAMP as well as to a variety of ECM
proteins. Autocrine and paracrine signals generated by proliferating
cystic epithelial differ from those produced by normal, quiescent
tubular epithelial cells and are likely to induce different, potentially
pathologic, responses in the underlying ﬁbroblasts which in turn may
have deleterious effects on the cystic epithelia.
Fibrosis develops secondary to cystic changes suggesting that if the
epithelial abnormality is corrected ﬁbrosis will be obviated. However
evidence derived mostly from the developmental and cancer
literature implies that ﬁbroblasts can induce changes in epithelial
phenotype and function [122]. Interestingly, preliminary co-culture
experiments combining normal or ADPKD ﬁbroblasts and normal
proximal tubular epithelial cells suggest that compared to normal
ﬁbroblasts, ADPKD ﬁbroblasts suppressed the expression of an
epithelial differentiation marker E-cadherin (unpublished data)
which is also associated with EMT [21] and is reduced in ADPKD
epithelial cells compared to their normal counterparts where it is
replaced by N-cadherin [123]. These data may suggest that correction
of the epithelial defect alone may not be sufﬁcient to prevent ﬁbrosis.
6. Fibrosis in APDKD: conclusions
Taken together the current data indicate that ﬁbrosis associated
with ADPKD shares at least some of the “classical” features of ﬁbrosis
in CKD (increased interstitial collagens, changes in MMPs, over-
expression of TIMP-1, over-expression of PAI-1 and increased TGFβ)
but that there are also some unique and stage-speciﬁc features.
Epithelial changes appear to precede and to drive changes in the
interstitium leading to the proposal that development of ﬁbrosis in
ADPKD is a biphasic process with alterations in the cystic epithelia
followed by changes in the interstitial ﬁbroblasts and that reciprocal
interactions between these cell types precipitate a progressive
accumulation of ECM in the interstitial compartment (Fig. 5). If
there is sequential induction of a ﬁbrotic cascade it might be possible
to intervene and prevent the process before the establishment of a
reciprocal “vicious cycle” of ﬁbrosis. The role of PC1 and PC2 in
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Fig. 5. Schematic of the proposed model of ﬁbrosis in ADPKD. Normal kidney structure and function are maintained by dynamic, homeostatic interactions between adjacent cell
populations. In ADPKD mutations in PKD1 or PKD2 lead to epithelial alterations including: αβ integrin proﬁle, downstream signalling including P-FAK, P-MAPK, P-JNK; MMP-2
secretion; altered response to TGFβ; changes in PC1 distribution/function. Epithelial changes in turn induce changes in underlying ﬁbroblasts including: synthesis/secretion
collagens I, III, MMPs, TIMPs, FGF-1, uPA; differentiation to myoﬁbroblasts expressing αSMA; induction of PC1. Dynamic reciprocal interactions between the two cell types (arrows)
dictate the overall pathological phenotype and may depend upon the PKD mutation.
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and, whether mutation per se leads to alterations in ﬁbroblast
phenotype or render the ﬁbroblasts susceptible to pro-ﬁbrotic signals
produced by epithelial cells all remain to be determined.
7. Anti-ﬁbrotic therapies in ADPKD
Slowing cystic expansion and the increase in kidney size in ADPKD,
thereby sparing normal renal tubule destruction, is key to delaying the
need for RRT. Since ﬁbrosis is a major component of the increase in
kidney size in ADPKD it follows that preventing or slowing ﬁbrosis
should retard disease progression with obvious therapeutic beneﬁts.
While work in CKDmay help identify potential targets for anti-ﬁbrotic
therapies [17,27,124] the development of effective anti-ﬁbrotic
strategies in ADPKD is dependent on understanding the precise
mechanisms underlying the initiation and progression of ﬁbrosis in
this disease and the role of the intrinsic genetic defect in these
processes. These studies are in their infancy but it seems likely that
future therapeutic strategies for ADPKD will be combinatorial,
targeting not only the proliferation and secretion defects in cystic
epithelial cells but also the pro-ﬁbrotic responses of the interstitial
ﬁbroblasts. For example, it has recently been shown that inhibition of
the KCa3.1 potassium channels suppresses cyst secretion and growth
and, in the UUO model of CKD, attenuates ﬁbrosis [125,126].
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